BIOMIMESYS® - EXTRACELLULAR MATRIX.
3D CELLULAR ASSAYS.
What is BIOMIMESYS® hydroscaffold?
BIOMIMESYS® is a unique groundbreaking 3D cell culture technology which associates the behavior of a solid scaffold and of a hydrogel which provide a cell culture microenvironment reproducing all aspects of human tissues, including matrix architecture, cellular organization, cell-cell and cell-matrix interactions.
Depending on the organ , extracellular matrix components may vary as well their proportions, allowing a more or less dense and compact cellular environment (different Elastic Modulus, porosity).
BIOMIMESYS® matrices are made of Hyaluronic Acid (HA), the main glycosaminoglycan (GAG) of the ECM, collagens and adhesion proteins. Our patented manufacturing process allow preserving the natural properties of HA and therefore synthesizing proprietary Hydroscaffold™.
Tuning the composition of BIOMIMESYS® matrix allows mimicking the cellular microenvironment of organ or tissue of interest.
The Challenge.
Conventional approaches - hydrogels, solid scaffolds or suspension cultures - struggle to recreate an extracellular matrix (ECM) faithful to that of native tissues. As a result, cultured cells lack the mechanical and biochemical signals they need to function properly, and the in vitro data they produce are difficult to transpose in vivo.
BioMIMESYS hydroscaffold addresses this critical situation for the development of physiologically relevant models, particularly for complex organs such as the brain, liver or tumor tissue by reproducing ECM with all physicochemical & biological properties.
ECM By Organ or Pathology.
Developed by HCS Pharma, BioMIMESYS® technology is now integrated into NETRI's organs-on-chip devices. BioiMIMESYS is a hydroscaffold™: an innovative blend between a solid scaffold and a hydrogel, based on hyaluronic acid and collagen. It makes it possible to recreate, in standard format (24 or 96 wells), an ECM specific to each organ - healthy or pathological - while retaining the essential biological, chemical and mechanical properties. This multi-organ compatibility makes BioMIMESYS® a central component of our Wetware platforms:
• BioMIMESYS Liver.
• BioMIMESYS Adipose Tissue.
• BioMIMESYS Brain.
• BioMIMESYS Oncology.
ECM BY ORGAN.
Liver Organoids.
Liver organoids grown in BioMIMESYS® Liver faithfully reproduce the key functions of the human liver :
• +20 to 30x albumin secretion compared with 2D cultures.
• High expression of CYP450 enzymes (CYP3A4, CYP1A1/2, CYP2B6).
• Formation of a network of canaliculi (Actin/MRP2).
• Response to treatment (e.g. lipid accumulation with amiodarone).
Liver organoids have already been used for applications in toxicology screening, metabolism and liver diseases (NASH, steatosis, fibrosis).
Adipose Tissue Organoids.
Human pre-adipocytes grown in BioMIMESYS® differentiate efficiently and retain their functionality for up to 2 months:
• Adapted ECM architecture (HA + collagens I and VI).
• Physiological elasticity (0.45 kPa).
• Compatible with primary cells and iPSCs.
Adipose Tissue organoids have already been used for applications in lipid metabolism, obesity, diabetes, nutritional screening.
Pancreas Spheroids.
PANC-1 cells grown in BioMIMESYS® form growing, homogeneous spheroids in BioMIMESYS®, providing a stable platform for:
• Analysis of tumor growth.
• Assessing the cytotoxicity of chemotherapies.
• The study of invasion and responses in the tumor microenvironment.
Pancreas spheroids have already been used for applications in pancreatic oncology, 3D tumor modeling, therapeutic response.
Brain Organoids.
NETRI recently announced the acquisition of HCS Pharma's assets and BioMIMESYS® products. BIOMIMESYS® is a breakthrough 3D cell culture matrix, mimicking in vivo conditions to recreate functional organs in vitro, enhancing predictivity.
• Long-term, functional 3D brain cultures.
• Parkinson's dieseases.
• Neurotoxicity.
ECM BY PATHOLOGY.
Organoids For Oncology.
BioMIMESYS® customizes the tumor microenvironment to better predict treatment efficacy. It is possible to modulate the rigidity (e.g. 1 kPa) and composition of the ECM matrix to simulate different tumor stages or types:
• Measured impact on cell proliferation.
• Marker monitoring (e.g. CD44, MDA-MB-231 spheroids, MCF7).
• Possibility of co-culturing with human immune cells.
BioMIMESYS® Oncology have already been used for applications in immuno-oncology, development of targeted therapies, resistance studies.
MAIN PIPELINE.
Oncology.
Explore pain management, efficacy and toxicity for oncology drug development with the Neurons as a Sensor (NaaS) suite.
• Chemotherapy-Induced Peripheral Neuropathy.
• Emetic Response.
• Efficacy testing of cancer therapeutics.
• Other Possibilities.
Immunology.
Explore inflammation as a central role in the regulation of neuronal signalling with NETRI’s immunology program.
• Inflammatory-mediated neuronal function.
• Evaluation of specific immune cell–neuron interactions.
• Other Possibilities.
Dermatology.
Test the effects of products on innervated skin or sensory neurons alone models.
• Atopic Dermatitis, Psoriasis, Skin irritation, Pruritus, Sensitization.
• Diabetes, Botox-like, Burn victim.
• Other Possibilities.
SECONDARY PIPELINE.
Neurodegenerative Diseases.
Model and/or diagnose neurodegenerative diseases with our brain-on-chip.
• Alzheimer's, Parkinson's, ALS, Dementia.
• Modeling.
• Diagnosis.
Neurotoxicology.
Explore toxicology with the Neurons as a Sensor (NaaS) suite.
• Food & Chemical Safety.
• Pesticide screening.
• Pharma neurotoxicology.
